Russia
Russia

Time filter

Source Type

Mountain View, CA, Nov. 14, 2016 (GLOBE NEWSWIRE) -- WSO2 today announced that the Eurasian Economic Union (EEU) is using the 100% open source WSO2 integration platform to power its transnational data exchange. The platform enables information to be shared easily across some 300 government agencies within the five countries forming the EUU: Armenia, Belarus, Kazakhstan, Kyrgyzstan and Russia. The exchange was created by WSO2 partner CROC, one of the largest integrators in Russia. The full case study can be downloaded at http://wso2.com/casestudies/eurasian-economic-union-relies-on-wso2-based-integration-platform-to-foster-economic-collaboration-between-nations. Integrating nations into a single economic bloc is a complex task, particularly as large amounts of data must be shared across nations. This data is key to decisions regarding customs processes, regulation of pharmaceuticals, agriculture, markets and monopolies and more. By enabling secure, cross-border data exchange across the EEU, CROC has enabled each of the nations within the Union to function as an integrated part of a larger economy, as well as help implement regional law and policy decisions. The new case study from WSO2 discusses the business and technology considerations CROC faced in designing the transnational data exchange, along with an overview of the resulting solution architecture. It also examines the integration platform within the exchange and the factors leading CROC to use WSO2 Enterprise Service Bus (WSO2 ESB) as the technology to power it. The case study then reviews key benefits that CROC and the EEU have realized. These include on-time project completion, the ability to exceed performance goals, the ease of exchanging data, and the flexibility to integrate diverse systems “The entry of Armenia and Kyrgyzstan to the EEU was facilitated by the WSO2-based integration platform, since it allowed the countries to exchange customs and tax data. Significantly, the flexibility of the platform also has allowed the Union to launch state-to-state data exchange processes without the need for new development,” said Alexey Smirnov, head of the Integration Solutions Practice at CROC. “Using WSO2 middleware, we have the confidence that we can meet the technical challenges of integrating the EUU with other governments and agencies around the world.” “Through its transnational data exchange, the Eurasian Economic Union is demonstrating how government institutions can effectively overcome the complexities of sharing data and services using enterprise-class open source software,” said Dr. Sanjiva Weerawarana, WSO2 founder, CEO and chief architect. “We are excited by CROC’s success in using our open source WSO2 ESB to implement the exchange’s integration platform and enable a new level of collaboration among EUU countries.” About CROC CROC has been working in the IT market since 1992 and today is one of the top 10 IT companies and the top three consulting businesses (Expert Rating Agency, 2016) in Russia. CROC is the Number 1 IT service provider in Russia (PAC, 2015), a leader in IT outsourcing (TAdviser, 2015), application management (PAC, 2015), BI, ERP solutions and e-document management systems (TAdviser, 2015) and telecommunications (Expert Rating Agency, 2016). CROC regularly ranks among the top three Russian IT service providers to the finance (RIA Rating, 2015), government (PAC, 2015), transportation (CNews, 2015), energy (TAdviser, 2016) and retail (CNews, 2016) sectors. For more information, please visit www.croc.com. About WSO2 WSO2 empowers enterprises to build connected businesses and accelerate their pace of innovation with the industry’s only lean, fully integrated, and 100% open source enterprise middleware platform. Using WSO2’s platform, enterprises have all the functionality to build, integrate, manage, secure and analyze their APIs, applications, Web services, and microservices—on-premises, in the cloud, on mobile devices, and across the Internet of Things. Leading enterprise customers worldwide rely on WSO2’s platform and its robust performance and governance for their mission-critical applications. Today, these businesses represent nearly every sector: health, financial, retail, logistics, manufacturing, travel, technology, telecom and more. Visit http://wso2.com to learn more, or check out the WSO2 community on the WSO2 Blog, Twitter, LinkedIn, and Facebook. Trademarks and registered trademarks are the properties of their respective owners.


News Article | December 14, 2016
Site: www.eurekalert.org

Five major Quebec cancer treatment centres are partnering with Montreal-based Exactis Innovation to build a coordinated network to match cancer patients to clinical trials based on the characteristics of their tumour through an innovative digital registry. The "Personalize My Treatment" (PMT) digital registry addresses the challenge of recruiting and matching cancer patients who have had their cancer molecularly profiled to clinical studies in areas of high unmet need. Under the agreement, the five partner institutions will begin enrolling cancer patients in the PMT program. The participating centres are: Centre hospitalier de l'Université de Montréal (CHUM), McGill University Health Centre (MUHC), the Segal Cancer Centre of the Jewish General Hospital, the CHU de Québec-Université Laval, and the Centre de recherche du Centre hospitalier universitaire de Sherbrooke (CRCHUS) intégré au CIUSSS de l'Estrie. "The Exactis PMT program and its partnership with Quebec's leading cancer treatment centres is an excellent example of the Quebec research community working in partnership for the benefit of Quebec patients," said Dr. Rémi Quirion, Chief Scientist of Quebec and Chair of the Quebec Research Funds. "The program's ability to provide international researchers with prompt access to specific populations of patients greatly enhances Quebec's ability to attract innovative research investment from the biotech and pharmaceutical sector that will benefit Quebec cancer patients." Patients participating in the PMT initiative consent to having their genetic and molecular information about their cancer tumour, as well as clinical data, stored in the Exactis digital registry and agree to be re-contacted for potential participation in future research projects, including possible clinical studies of new treatments targeted to their specific type of cancer. "Understanding cancer through its molecular and immune characteristics allows us to target novel medicines to the patient's disease with the goal of improving treatment response. As cancer is more precisely defined, matching patients to clinical trials has become more challenging," said Dr. Gerald Batist, Co-Founder and Chief Medical Officer of Exactis Innovation and Director of the Segal Cancer Centre of the Jewish General Hospital. "No single cancer centre, no matter how large, can identify enough patients of a very specific type eligible for studies using precision medicines. The Exactis PMT program allows us to pool patients from a coordinated network of centres and to attract the most innovative research to Canada and Quebec." Recent research has led to much greater knowledge about the individual molecular characteristics of cancer, leading to the development of precision medicine - tailoring treatment decisions to patients based on the molecular or genetic signature of their disease. "We are pleased to be a founding partner of the Exactis PMT program to promote patient access to personalized cancer treatments," said Andy Chabot, President and CEO of the Cancer Research Society. "The more cancer research we can attract through initiatives such as this, the more patients will benefit." "Our partnership with the major cancer centres in Quebec provides us with a critical scale of operations to expand the program to help patients and researchers throughout Canada," said Richard Fajzel, President and CEO of Exactis Innovation. "The development and growth of a network initiative such as PMT is possible only through the commitment and collaboration of multiple founding partners from the public and private sectors over the long-term such as the Cancer Research Society and founding support through the federal Business Led-Networks of Centers of Excellence program." The Exactis PMT program is a non-profit public-private partnership with funding from the federal and provincial governments, research organizations, biopharmaceutical companies and patient groups. Founded in 2014, Exactis Innovation (Exactis) is a pan-Canadian, non-profit organization that improves cancer care for Canadians by addressing the challenge of recruiting and matching cancer patients to clinical studies for targeted therapies that could benefit them. The Exactis solution is a first-of-its-kind patient registry -- Personalize My Treatment (PMT) - where patients are recruited by their cancer care institution and agree to have detailed genetic data about their cancer stored in a digital registry and also agree to be contacted if they are considered suitable for future clinical studies that match their cancer characteristics. Exactis is building its network of PMT cancer centres across Canada to promote research and the better use of technology and resources for the benefit of patients in areas of high unmet need. Exactis is funded through grants from the Networks of Centres of Excellence, various Canadian research organizations and biopharmaceutical companies. Exactis is a partner of the Consortium de recherche en oncologie clinique du Québec (Q-CROC), financed by Fonds de partenariat pour un Québec innovant et en santé. For details, visit exactis.ca


PubMed | University of Reims Champagne Ardenne, CNRS Biometry and Evolutionary Biology Laboratory, University Claude Bernard Lyon 1, Office National de la Chasse et de la Faune Sauvage and CROC
Type: | Journal: International journal for parasitology. Parasites and wildlife | Year: 2014

Toxoplasmosis is a major zoonosis, and its prevention requires multiple approaches due to the complex life-cycle of its causative agent, Toxoplasma gondii. Environmental contamination by oocysts is a key factor in the transmission of T. gondii to both humans and meat-producing animals; however, its spatial and temporal variations are poorly understood. We analysed the distribution of T. gondii seropositivity in a sample of 210 cats, including the European wildcat (Felis silvestris silvestris), the domestic cat (Felis silvestris catus) and their hybrids that were collected in Central and Eastern France between 1996 and 2006. We searched for spatial variability among communes and temporal variations among years to relate this variability to landscape and meteorological conditions, which can affect the population dynamics of rodent hosts and the survival of oocysts. The overall seroprevalence was 65.2% (95% CI: 58.6-71.4). As expected, adults were more often infected than young individuals, while the occurrence of infection was not related to cat genotypes. Seroprevalence correlated significantly with farm density and the North-Atlantic Oscillation index, which describes temporal variations of meteorological conditions at the continental scale. The highest seroprevalence values were obtained in areas with high farm densities and during years with cool and moist winters. These results suggest that both farming areas and years with cool and wet winters are associated with increased T. gondii seroprevalence in cats. As cat infection determines the environmental contamination by oocysts, climate and landscape characteristics should be taken into account to improve the risk analysis and prevention of T. gondii.


Livlnskiy V.Y.,CROC | Zeybot R.R.,CROC | Zaedinov R.V.,CROC
Neftyanoe Khozyaistvo - Oil Industry | Year: 2011

Reduction Total cost of ownership of the IT Infrastructure. Migration of geophysical calculations and modeling in a public cloud. Approaches to Increase of elasticity of the computing environment.


Afonso E.,CNRS Biometry and Evolutionary Biology Laboratory | Germain E.,CROC | Poulle M.-L.,University of Reims Champagne Ardenne | Ruette S.,Office National de la Chasse et de la Faune Sauvage | And 6 more authors.
International Journal for Parasitology: Parasites and Wildlife | Year: 2013

Toxoplasmosis is a major zoonosis, and its prevention requires multiple approaches due to the complex life-cycle of its causative agent, Toxoplasma gondii. Environmental contamination by oocysts is a key factor in the transmission of T. gondii to both humans and meat-producing animals; however, its spatial and temporal variations are poorly understood. We analysed the distribution of T. gondii seropositivity in a sample of 210 cats, including the European wildcat (Felis silvestris silvestris), the domestic cat (Felis silvestris catus) and their hybrids that were collected in Central and Eastern France between 1996 and 2006. We searched for spatial variability among communes and temporal variations among years to relate this variability to landscape and meteorological conditions, which can affect the population dynamics of rodent hosts and the survival of oocysts. The overall seroprevalence was 65.2% (95% CI: 58.6-71.4). As expected, adults were more often infected than young individuals, while the occurrence of infection was not related to cat genotypes. Seroprevalence correlated significantly with farm density and the North-Atlantic Oscillation index, which describes temporal variations of meteorological conditions at the continental scale. The highest seroprevalence values were obtained in areas with high farm densities and during years with cool and moist winters. These results suggest that both farming areas and years with cool and wet winters are associated with increased T. gondii seroprevalence in cats. As cat infection determines the environmental contamination by oocysts, climate and landscape characteristics should be taken into account to improve the risk analysis and prevention of T. gondii. © 2013 The Authors.

Loading CROC collaborators
Loading CROC collaborators